Unity Biotechnology, Inc. (0YC0.L)
USD 1.13
(9.82%)
USD 1.13
(9.82%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -39.86 Million USD | 30.97% |
| 2022 | -57.74 Million USD | 3.82% |
| 2021 | -60.03 Million USD | 34.65% |
| 2020 | -91.86 Million USD | -22.7% |
| 2019 | -74.87 Million USD | 2.0% |
| 2018 | -76.39 Million USD | -71.08% |
| 2017 | -44.65 Million USD | -46.88% |
| 2016 | -30.4 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -5.79 Million USD | -33.44% |
| 2024 Q2 | -5.27 Million USD | 8.83% |
| 2024 Q3 | -6.48 Million USD | -22.77% |
| 2023 Q2 | -12.2 Million USD | -1.04% |
| 2023 Q4 | -4.33 Million USD | 71.62% |
| 2023 FY | -39.86 Million USD | 30.97% |
| 2023 Q1 | -12.07 Million USD | 12.21% |
| 2023 Q3 | -15.28 Million USD | -25.27% |
| 2022 Q4 | -13.75 Million USD | 3.69% |
| 2022 Q3 | -14.28 Million USD | -1.93% |
| 2022 FY | -57.74 Million USD | 3.82% |
| 2022 Q2 | -14.01 Million USD | 28.35% |
| 2022 Q1 | -19.56 Million USD | -82.95% |
| 2021 Q1 | -15.75 Million USD | 19.56% |
| 2021 FY | -60.03 Million USD | 34.65% |
| 2021 Q4 | -10.69 Million USD | 35.0% |
| 2021 Q3 | -16.45 Million USD | 7.72% |
| 2021 Q2 | -17.82 Million USD | -13.14% |
| 2020 Q1 | -28.03 Million USD | -55.53% |
| 2020 FY | -91.86 Million USD | -22.7% |
| 2020 Q4 | -19.58 Million USD | 28.91% |
| 2020 Q2 | -18.66 Million USD | 33.42% |
| 2020 Q3 | -27.55 Million USD | -47.6% |
| 2019 Q3 | -21.71 Million USD | 8.29% |
| 2019 Q1 | -18.76 Million USD | 14.37% |
| 2019 FY | -74.87 Million USD | 2.0% |
| 2019 Q4 | -18.02 Million USD | 16.96% |
| 2019 Q2 | -23.67 Million USD | -26.14% |
| 2018 Q2 | -20 Million USD | -23.98% |
| 2018 FY | -76.39 Million USD | -71.08% |
| 2018 Q1 | -16.13 Million USD | -28.62% |
| 2018 Q4 | -21.91 Million USD | -19.46% |
| 2018 Q3 | -18.34 Million USD | 8.28% |
| 2017 Q2 | -11.42 Million USD | -27.92% |
| 2017 FY | -44.65 Million USD | -46.88% |
| 2017 Q1 | -8.93 Million USD | 0.0% |
| 2017 Q4 | -12.54 Million USD | -6.75% |
| 2017 Q3 | -11.75 Million USD | -2.82% |
| 2016 FY | -30.4 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| uniQure N.V. | -308.47 Million USD | 87.078% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 26.441% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 54.951% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 88.679% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 85.565% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 66.367% |
| Imunon, Inc. | -19.51 Million USD | -104.253% |
| Dynavax Technologies Corporation | -6.38 Million USD | -523.885% |
| Editas Medicine, Inc. | -153.21 Million USD | 73.985% |
| FibroGen, Inc. | -284.23 Million USD | 85.976% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 91.023% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 5.543% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 115.963% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 92.563% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 3128.875% |
| Verastem, Inc. | -87.36 Million USD | 54.376% |
| Zoetis Inc. | 2.34 Billion USD | 101.701% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.101% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 84.54% |
| Homology Medicines, Inc. | -53.74 Million USD | 25.832% |
| Nektar Therapeutics | -276.05 Million USD | 85.561% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 53.595% |
| Perrigo Company plc | -12.7 Million USD | -213.858% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 80.951% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.538% |
| Illumina, Inc. | -1.16 Billion USD | 96.567% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 100.665% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 102.935% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 63.947% |
| Waters Corporation | 642.23 Million USD | 106.206% |
| Biogen Inc. | 1.16 Billion USD | 103.433% |
| Evolus, Inc. | -61.68 Million USD | 35.381% |
| Adicet Bio, Inc. | -142.65 Million USD | 72.059% |
| bluebird bio, Inc. | -211.91 Million USD | 81.19% |
| Geron Corporation | -184.12 Million USD | 78.352% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 90.946% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 73.704% |
| Myriad Genetics, Inc. | -112 Million USD | 64.411% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 91.716% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 105.053% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 10.634% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 123.776% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.008% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 103.215% |
| OPKO Health, Inc. | -188.86 Million USD | 78.895% |
| Exelixis, Inc. | 207.76 Million USD | 119.185% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 137.554% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 16.093% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 83.339% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 89.118% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 114.155% |
| Blueprint Medicines Corporation | -506.98 Million USD | 92.138% |
| Insmed Incorporated | -749.56 Million USD | 94.682% |
| TG Therapeutics, Inc. | 12.67 Million USD | 414.552% |
| Incyte Corporation | 597.59 Million USD | 106.67% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 94.759% |